TOP TEN perturbations for 39820_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39820_at
Selected probe(set): 221714_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39820_at (221714_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample
Relative Expression (log2-ratio):-2.640833Number of Samples:5 / 7
Experimental | E. coli study 2 |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli. | |
Control | unstimulated, normal monocyte-derived macrophage sample |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated. |
diabetes type 2 study 27 (LCM) / diabetes type 2 study 27 (enzymatic)
Relative Expression (log2-ratio):1.7988801Number of Samples:34 / 19
Experimental | diabetes type 2 study 27 (LCM) |
Pancreatic islet samples obtained from type 2 diabetic (T2D) phenotyped pancreatectomized patients (PPP) and isolated by laser capture microdissection (LCM). Islets specimens were retrieved by LCM from snap-frozen surgical specimen from patients who underwent pancreatectomy for pancreatic diseases. Histopathology of the resected tissue did not reveal insulitis in any PPP. Patients age <18 years were excluded. Patients with type 2 diabetes had fasting glycemia ≥7.0 mmol/l; HbA1C ≥6.5% and history of diabetes for >1 year. | |
Control | diabetes type 2 study 27 (enzymatic) |
Pancreatic islet samples obtained from type 2 diabetic (T2D) patients and isolated by enzymatic digestion. Well-preserved islets were isolated by collagenase digestion of pancreas from brain-dead organ donors which suffered from type 2 diabetes. After 2±1 days of culture, islets were successfully hand-picked and processed for further analyses. Type 2 diabetes was diagnosed based on clinical history, treatment with glucose-lowering drugs, and lack of anti-GAD65 autoantibodies. |
E. coli study 1 / unstimulated, normal monocyte-derived macrophage sample
Relative Expression (log2-ratio):-1.6799393Number of Samples:12 / 16
Experimental | E. coli study 1 |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli. | |
Control | unstimulated, normal monocyte-derived macrophage sample |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated. |
cholesterol study 1 / vehicle (DME) treated bronchial epithelial cell sample
Relative Expression (log2-ratio):1.3971539Number of Samples:3 / 17
Experimental | cholesterol study 1 |
Bronchial epithelial cells (NHBE) treated with cholesterol (2000 ng/ml; vendor: Sigma / catalog number: C3045 / catalog name: Cholesterol [57-88-5]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). | |
Control | vehicle (DME) treated bronchial epithelial cell sample |
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):-1.3940277Number of Samples:20 / 19
Experimental | atopic dermatitis study 12 (non-lesional; adults) |
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
Control | atopic dermatitis study 12 (non-lesional; children) |
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
HIF-1a depletion study 2 (hypoxia; AB81) / hypoxia study 11 (AB81)
Relative Expression (log2-ratio):-1.3353596Number of Samples:3 / 3
Experimental | HIF-1a depletion study 2 (hypoxia; AB81) |
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a (Hypoxia-inducible factor 1-alpha) 24 hours after treatment with hypoxia (1% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. | |
Control | hypoxia study 11 (AB81) |
Human podocyte cell line AB81 treated with hypoxia (1% O2) for 24 hours. Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):1.2803392Number of Samples:3 / 4
Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
systemic lupus erythematosus study 13 (untreated) / normal PBMC sample
Relative Expression (log2-ratio):1.169158Number of Samples:4 / 5
Experimental | systemic lupus erythematosus study 13 (untreated) |
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists. | |
Control | normal PBMC sample |
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. |
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):1.1674271Number of Samples:4 / 6
Experimental | F. tularensis study 1 (tularensis Schu S4) |
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
psoriasis study 5 (Zaba; lesional; etanercept; 4wk; resp.) / psoriasis study 5 (Zaba; lesional; etanercept; 4wk; non-resp.)
Relative Expression (log2-ratio):1.140811Number of Samples:9 / 4
Experimental | psoriasis study 5 (Zaba; lesional; etanercept; 4wk; resp.) |
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis four weeks after starting biweekly therapy with etanercept (s.c.). Patients were classified as responders to etanercept treatment. ATC code: | |
Control | psoriasis study 5 (Zaba; lesional; etanercept; 4wk; non-resp.) |
Lesional skin punch biopsies derived from patients with moderate to severe psoriasis four weeks after starting biweekly therapy with etanercept (s.c.). Patients were classified as non-responders to etanercept treatment. ATC code: |